Cognition Therapeutics Non Current Liabilities Total Over Time

CGTX Stock  USD 0.43  0  0.93%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cognition Therapeutics Performance and Cognition Therapeutics Correlation.
For more information on how to buy Cognition Stock please use our How to Invest in Cognition Therapeutics guide.
  
Non Current Liabilities Total is likely to drop to about 494 K in 2024.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cognition Therapeutics. If investors know Cognition will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cognition Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.96)
Return On Assets
(0.94)
Return On Equity
(1.08)
The market value of Cognition Therapeutics is measured differently than its book value, which is the value of Cognition that is recorded on the company's balance sheet. Investors also form their own opinion of Cognition Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cognition Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cognition Therapeutics' market value can be influenced by many factors that don't directly affect Cognition Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cognition Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cognition Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cognition Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Non Current Liabilities Total Analysis

Compare Cognition Therapeutics and related stocks such as Equillium, DiaMedica Therapeutics, and Valneva SE ADR Non Current Liabilities Total Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
EQ8.8 M8.8 M8.8 M8.8 M8.8 M8.8 M8.8 M8.8 M200 K9.8 M8.3 M10 M14.4 M384 K364.8 K
DMAC388.2 K388.2 K388.2 K388.2 K388.2 K388.2 K0.00.018 K118 K53 KK400 K317 K158.5 K
VALN6.3 M19.3 M17.7 M82.2 M75.7 M84.5 M67.9 M59 M43.8 M88.3 M195.9 M277.8 M124.2 M173 M181.6 M
VANI8.3 M8.3 M8.3 M19.2 M2.4 M2.4 M2.4 M2.4 M2.4 M2.4 M1.1 M902 K2.1 M19.3 M20.3 M
DNLI48.8 M48.8 M48.8 M48.8 M48.8 M48.8 M7.4 M6.8 M82.4 M113 M382.1 M63.6 M53.9 M45 M42.7 M
DNTH1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M6.2 M6.3 M21.3 M119.3 M904 K858.8 K
DOMH900 K47.7 K3.2 M20 M6.3 M488 K3.3 M2.3 M0.068 K567 K381 K680 KMM
VCEL34.5 M40 KK2.4 M109 K71 K11 M18.9 M1.7 M22.4 M48.9 M47.2 M43.3 M82 M86.1 M
VCNX1.7 M1.7 M1.7 M1.7 M1.7 M1.7 M1.7 M3.2 M0.03.7 M1.1 M175 K247 K26 K24.7 K
VCYT35 K35 K5.2 M7.8 M6.3 M9.3 M29.9 M29.4 M27.8 M18.3 M19.1 M27.2 M18.6 M9.6 M17.6 M

Cognition Therapeutics and related stocks such as Equillium, DiaMedica Therapeutics, and Valneva SE ADR Non Current Liabilities Total description

My Equities

My Current Equities and Potential Positions

Cognition Therapeutics
CGTX
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationPennsylvania; U.S.A
ExchangeNASDAQ Exchange
USD 0.434

Additional Tools for Cognition Stock Analysis

When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.